Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605651 | 0.91 | SMN1; SMN2 (0.43) | POLBHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3606175 | 0.87 | ALDH1A1 (0.41) | PPM1BPTPN1PPP1CCPOLBHPGD | |
| SCHEMBL3611663 | 0.84 | HTT (0.34) | HPGDLMNASMN1; SMN2ALDH1A1PIK3CD | |
| SCHEMBL3609381 | 0.83 | PIK3CD (0.36) | SMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL3605080 | 0.83 | PPM1B (0.39) | PPM1BPTPN1PPP1CCPOLBHPGD | |
| SCHEMBL3599574 | 0.81 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL3589754 | 0.80 | RECQL (0.38) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL5360827 | 0.76 | PPM1B (0.51) | PPM1BPTPN1PPP1CCPOLBHPGD | |
| SCHEMBL23295632 | 0.74 | L3MBTL1 (0.39) | PPM1BPTPN1PPP1CCLMNAALDH1A1 | |
| SCHEMBL3603637 | 0.74 | SMN1; SMN2 (0.44) | POLBHPGDLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741497-B2 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1700852-A1 | PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN | Ube Industries, Ltd. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | DHPS, OXER1, CYP4A11 | PPM1B 4329/4885PTPN1 4368/4885PPP1CC 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.